Differences

This shows you the differences between two versions of the page.

--- home:protocol:olmesartan:safety [06.11.2019] – [Data supporting the safety of higher than typical dosing frequencies] sallieq
+++ home:protocol:olmesartan:safety [07.12.2019] – [Recent research] sallieq
@@ Line 122: / Line 122: @@
 [[http://doi.org/10.5761/atcs.oa.11.01691|angiotensin II and aldosterone are decreased in a change-over from candesartan to olmesartan]]
+With the halt of reimbursement of olmesartan, there was a decrease in the prescription of ARB in France. When olmersartan was replaced by another ARB, a worse blood pressure control was observed in treated hypertensive patients.  (({{pubmed>long:29807620 }}))
+==== Enteropathy ====
+The incidence of this adverse drug reaction is not entirely clear, although it is thought to be rare.
+(({{pubmed>long:26997446}}))
+Seven cases (2.8%) reported recurrence of symptoms after restarting olmesartan (({{pubmed>long:31217979}}))
+Although enteropathy is rare, clinicians should remain vigilant of this potential adverse event even years after medication initiation.
+(({{pubmed>long:31217979}}))
+results suggest that SMEEDS formulation improves dissolution and oral bioavailability of OM while reducing adverse effects (celiac-like enteropathy or diarrhea ). (({{pubmed>long:30986085}}))
+==== Collagenous enteritis, a genetic problem? ====
+Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis.
+All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications, smoking history, demographics, histology, clinical management, and follow-up were recorded. A total of 32 subjects were included. In contrast to celiac disease, subjects with collagenous enteritis were mostly elderly (median age at diagnosis, 69 y; range, 33 to 84 y). Seventy percent of collagenous enteritis subjects harbored celiac disease susceptibility alleles HLA-DQ2/DQ8; however, only 1 subject had elevated serum levels of celiac disease-associated autoantibodies while on a gluten-containing diet. Furthermore, 56% of subjects were taking nonsteroidal anti-inflammatory drugs, 36% proton-pump inhibitors, 28% statins, and 32% olmesartan at the time of diagnosis. Discontinuation of olmesartan and treatments with steroids and/or gluten-free diet resulted in symptomatic and histologic improvement. (({{pubmed>long:29324472 }}))
+Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population.  (({{pubmed>long:29172402}}))
 ===== Notes and comments =====

home/protocol/olmesartan/safety.txt · Last modified: 09.14.2022 by 127.0.0.1